Tokyo, June 25, 2015 – Sandoz has announced the Japanese market introduction of three new products including clopidogrel, tacrolimus and pitavastatin (line extension).
Clopidogrel, a generic version of Sanofi’s Plavix®, is used for suppression of recurrence of ischemic cerebrovascular disorder. Tacrolimus, a generic version of Astellas’s PROGRAF®, is used among others to prevent organ transplant rejection (kidney, liver, heart, lung, pancreas, small intestine). Pitavastatin, a generic version of Kowa’s LIVALO®, is used for lowering cholesterol.
“We are pleased to introduce three new important generic medicines in Japan. These will provide patients with alternative treatments and support further the penetration of generic medicines in Japan in line with the government’s efforts,” said Tomo Hasegawa, Country Head of Sandoz Japan. “Generic medicines are a key contributor to reducing the costs of healthcare and Sandoz is proud to play its role in furthering access to affordable high-quality, medicines.”
The foregoing release contains forward-looking statements that can be identified by words such as “launches,” “introduction,” “will,” or similar terms, or by express or implied discussions regarding potential revenues from Clopidogrel, Tacrolimus and Pitavastatin. You should not place undue reliance on these statements. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that Clopidogrel, Tacrolimus and Pitavastatin will be commercially successful in the future. In particular, management’s expectations could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; competition in general, including potential approval of additional versions of Clopidogrel, Tacrolimus and Pitavastatin; national trends toward health care cost containment, including ongoing pricing pressures; unexpected patent litigation outcomes; unexpected manufacturing issues; general economic and industry conditions, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
Sandoz, a division of Novartis, is a global leader in generic pharmaceuticals, driving sustainable access to high-quality healthcare. Sandoz employs more than 26,000 people worldwide and supplies a broad range of affordable products to patients and customers around the globe.
The Sandoz global portfolio comprises approximately 1,100 molecules, which accounted for 2014 sales of USD 9.6 billion. Sandoz holds the global #1 position in biosimilars as well as in generic anti-infectives, ophthalmics and transplantation medicines. Sandoz also holds leading global positions in key therapeutic areas ranging from generic injectables, dermatology and respiratory to cardiovascular, metabolism, central nervous system, pain and gastrointestinal.
Sandoz develops, produces and markets finished dosage form (FDF) medicines as well as intermediary products including active pharmaceutical ingredients (APIs) and biotechnological substances. Nearly half of the Sandoz portfolio is in differentiated products – medicines that are scientifically more difficult to develop and manufacture than standard generics.
In addition to strong organic growth since consolidating its generics businesses under the Sandoz brand name in 2003, Sandoz has consistently driven growth in selected geographies and differentiated product areas through a series of targeted acquisitions, including Hexal (Germany), EBEWE Pharma (Austria), and Fougera Pharmaceuticals (US).